(Q46850358)

English

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16353201

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16353201

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

13

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

Alessandra Ferrajoli

4

object named as

Alessandra Ferrajoli

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

3

object named as

Stefan Faderl

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

William G Wierda

1

object named as

William Wierda

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

11

object named as

Francis Giles

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

Guillermo Garcia-Manero

7

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

Jorge Eduardo Cortes

9

object named as

Jorge Cortes

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

Michael J. Keating

14

object named as

Michael Keating

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

2

object named as

Susan O'brien

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

12

object named as

Susan Lerner

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

Farhad Ravandi-Kashani

10

object named as

Farhad Ravandi-Kashani

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16353201

author name string

Xuemei Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16353201

Kim-Anh Do

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16353201

Deborah Thomas

8

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16353201

language of work or name

0 references

publication date

1 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16353201

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16353201

106

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16353201

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16353201

337-345

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16353201

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21554

21 January 2018

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21554

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21554

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21554

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21554

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21554

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21554

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21554

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21554

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21554

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of observational studies and randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21554

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21554

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21554

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16353201

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16353201

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46850358&oldid=2134704951"